
浏览全部资源
扫码关注微信
1.南京中医药大学 第一临床医学院,南京 210023
2.南京市中医院,南京 210012
3.江苏省中医药防治肿瘤协同创新中心,南京 210023
4.南京中医药大学 附属医院 江苏省中医院,南京 210029
刘见荣,博士,主治中医师,从事中医肿瘤临床及研究,E-mail: liujianrong-zz@163.com
范旻旻,博士,讲师,从事中医药防治肿瘤研究,E-mail:fanminmin825@163.com
收稿日期:2021-10-20,
网络出版日期:2022-01-29,
纸质出版日期:2022-07-20
移动端阅览
刘见荣,黄敏,范旻旻等.参白解毒方通过调控PTEN/PI3K/Akt信号通路抑制结直肠癌细胞增殖[J].中国实验方剂学杂志,2022,28(14):36-43.
LIU Jianrong,HUANG Min,FAN Minmin,et al.Shenbai Jiedu Prescription Inhibits Proliferation of Colorectal Cancer Cells by Regulating PTEN/PI3K/Akt Signaling Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(14):36-43.
刘见荣,黄敏,范旻旻等.参白解毒方通过调控PTEN/PI3K/Akt信号通路抑制结直肠癌细胞增殖[J].中国实验方剂学杂志,2022,28(14):36-43. DOI: 10.13422/j.cnki.syfjx.20220721.
LIU Jianrong,HUANG Min,FAN Minmin,et al.Shenbai Jiedu Prescription Inhibits Proliferation of Colorectal Cancer Cells by Regulating PTEN/PI3K/Akt Signaling Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(14):36-43. DOI: 10.13422/j.cnki.syfjx.20220721.
目的
2
研究参白解毒方基于磷酸酶及张力蛋白同源物(PTEN)/磷脂酰肌醇-3激酶(PI3K)/蛋白激酶B(Akt)信号通路抑制结直肠癌细胞HCT116增殖的作用机制。
方法
2
采用水提醇沉法提取参白解毒方有效部位进行冻干粉制备;体外培养HCT116细胞,用参白解毒方(2、4、8、16 g·L
-1
)对HCT116细胞进行处理,采用噻唑蓝(MTT)比色法检测参白解毒方对HCT116细胞增殖的抑制作用;实时荧光定量聚合酶链式反应(Real-time PCR)检测细胞PTEN、PI3K、Akt、糖原合成酶激酶-3
β
(GSK-3
β
)、c-核蛋白类基因(c-Myc)、生存素(Survivin)和细胞周期蛋白D
1
(CyclinD
1
)mRNA表达水平;蛋白免疫印迹法(Western blot)检测PTEN、磷酸化磷酸酶及张力蛋白同源物(p-PTEN)、PI3K、Akt、磷酸化蛋白激酶B(p-Akt)、GSK-3
β
、磷酸化糖原合成酶激酶-3(p-GSK-3
β
)、c-Myc、Survivin、CyclinD
1
的蛋白表达水平;免疫荧光检测
β
-连环蛋白(
β
-catenin)入核情况。
结果
2
与空白组比较,参白解毒方各质量浓度均可以显著抑制HCT116细胞的增殖(
P
<
0.01),且具有浓度依赖性。与空白组比较,参白解毒方处理细胞后PTEN、GSK-3
β
mRNA表达水平均上调,PI3K、Akt、c-Myc、Survivin、CyclinD
1
mRNA表达水平均下调(
P
<
0.01);细胞PTEN、p-PTEN和GSK-3
β
蛋白表达水平上调,PI3K、Akt、p-Akt、GSK-3
β
、p-GSK-3
β
、c-Myc、Survivin、CyclinD
1
蛋白表达水平均下调(
P
<
0.05,
P
<
0.01)。免疫荧光结果显示参白解毒方可以抑制结直肠癌细胞HCT116中
β
-catenin的入核。
结论
2
参白解毒方可以抑制结直肠癌细胞HCT116的增殖,其作用机制可能是通过调节PTEN/PI3K/Akt信号通路。
Objective
2
To study the mechanism of Shenbai Jiedu prescription inhibiting the proliferation of HCT116 colorectal cancer (CRC) cells by regulating the phosphatase and tensin homolog deleted on chromosome ten (PTEN)/phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (Akt) signaling pathway.
Method
2
Shenbai Jiedu prescription was extracted by water extraction and alcohol precipitation to prepare freeze-dried powder. HCT116 cells were cultured
in vitro
, and treated with different concentrations of Shenbai Jiedu prescription (2, 4, 8, 16 g·L
-1
). The inhibitory effect of Shenbai Jiedu prescription on the proliferation of HCT116 cells was tested by methyl thiazolyl tetrazolium (MTT). Real-time quantitative PCR was used to detect the mRNA expression levels of PTEN, PI3K, Akt, glycogen synthase kinase-3
β
(GSK-3
β
), c-Myc, survivin and Cyclin D
1
. Western blot was employed to measure the protein expression levels of PTEN, phosphorylated PTEN (p-PTEN), PI3K, Akt, phosphorylated Akt (p-Akt), GSK-3
β
, phosphorylated GSK-3
β
(p-GSK-3
β)
, c-Myc, survivin and Cyclin D
1
,
β
-catenin nuclear import was explored by immunofluorescence assay.
Result
2
Compared with the control group, Shenbai Jiedu prescription inhibited the proliferation of HCT116 cells in a dose-dependent manner (
P
<
0.01). Compared with the control group, the mRNA expression levels of PTEN and GSK-3
β
were up-regulated whereas those of PI3K, Akt, c-Myc, survivin and CyclinD
1
were down-regulated after treatment with Shenbai Jiedu prescription (
P
<
0.01). The protein expression levels of PTEN, p-PTEN and GSK-3
β
were up-regulated whereas those of PI3K, Akt, p-Akt, GSK-3
β
, p-GSK-3
β
, c-Myc, survivin and CyclinD
1
were down-regulated (
P
<
0.05,
P
<
0.01). Immunofluorescence assay showed that Shenbai Jiedu prescription suppressed
β
-catenin nuclear import in HCT116 cells.
Conclusion
2
Shenbai Jiedu prescription inhibited the proliferation of HCT116 cells via the mechanism of regulating the PTEN/PI3K/Akt signaling pathway.
SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 .
YANG Q , JIANG W , HOU P . Emerging role of PI3K/Akt in tumor-related epigenetic regulation [J]. Semin Cancer Biol , 2019 , 59 : 112 - 124 .
耿军辉 , 张丽军 , 王亚丽 , 等 . PI3K/Akt信号通路与肿瘤血管新生的研究进展 [J]. 现代肿瘤医学 , 2018 , 26 ( 9 ): 1462 - 1466 .
李建 , 周怀君 . PI3K/Akt信号通路在肿瘤研究中的进展 [J]. 东南大学学报:医学版 , 2014 , 33 ( 3 ): 392 - 395 .
TSAI W B , AIBA I , LONG Y , et al . Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells [J]. Cancer Res , 2012 , 72 ( 10 ): 2622 - 2633 .
HEERY R , FINN S P , CUFFE S , et al . Long non-coding RNAs: Key regulators of epithelial-mesenchymal transition, tumour drug resistance and cancer stem cells [J]. Cancers , 2017 , 9 ( 4 ): 38 .
RUBINSTEIN M R , WANG X , LIU W , et al . Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin [J]. Cell Host Microbe , 2013 , 14 ( 2 ): 195 - 206 .
WANG L L , HAO S , ZHANG S , et al . PTEN/PI3K/Akt protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases [J]. Hum Pathol , 2017 , 61 : 49 - 57 .
ZHANG L L , MU G G , DING Q S , et al . Phosphatase and tensin homolog (PTEN) represses colon cancer progression through inhibiting paxillin transcription via PI3K/Akt/NF-kappaB pathway [J]. J Biol Chem , 2015 , 290 ( 24 ): 15018 - 15029 .
LI L , ZHU X , SHOU T , et al . MicroRNA-28 promotes cell proliferation and invasion in gastric cancer via the PTEN/PI3K/Akt signalling pathway [J]. Mol Med Rep , 2018 , 17 ( 3 ): 4003 - 4010 .
ZHANG R , LI G , ZHANG Q , et al . Hirsutine induces mPTP-dependent apoptosis through ROCK1/PTEN/PI3K/GSK3beta pathway in human lung cancer cells [J]. Cell Death Dis , 2018 , 9 ( 6 ): 598 .
QIN Y , HUO Z , SONG X , et al . mir-106a regulates cell proliferation and apoptosis of colon cancer cells through targeting the PTEN/PI3K/Akt signaling pathway [J]. Oncol Lett , 2018 , 15 ( 3 ): 3197 - 3201 .
程海波 , 李柳 , 吴勉华 , 等 . 癌毒病机理论辨治肠癌探讨 [J]. 时珍国医国药 , 2017 , 28 ( 10 ): 2487 - 2488 .
江东 . 基于炎癌转化探讨参白解毒方抑制结直肠腺瘤癌变的药效及机制研究 [D]. 南京 : 南京中医药大学 , 2021 .
程海波 , 周仲瑛 , 李柳 , 等 . 基于癌毒病机理论的中医肿瘤临床辨治体系探讨 [J]. 中医杂志 , 2015 , 56 ( 23 ): 1989 - 1992 .
王林娜 , 张清泉 , 侯素平 , 等 . RegⅣ、EGFR和Survivin在结直肠腺瘤癌变过程中的表达及意义 [J]. 中国现代医学杂志 , 2017 , 27 ( 6 ): 44 - 49 .
YANG J , GONG Z , SHEN X , et al . FSH receptor binding inhibitor depresses carcinogenesis of ovarian cancer via decreasing levels of K-Ras, c-Myc and FSHR [J]. Anim Biotechnol , 2021 , 32 ( 1 ): 84 - 91 .
LEE D H , KIM G W , YOO J , et al . Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc [J]. Cell Death Dis , 2021 , 12 ( 1 ): 89 .
鲁鑫宇 , 王忠泽 , 万思成 , 等 . 粉防己碱对胶质母细胞瘤细胞增殖、迁移和侵袭的影响及其机制研究 [J]. 中国中药杂志 , 2021 , 46 ( 24 ): 6520 - 6529 .
HUANG W , DONG S , CHA Y , et al . SNHG11 promotes cell proliferation in colorectal cancer by forming a positive regulatory loop with c-Myc [J]. Biochem Biophys Res Commun , 2020 , 527 ( 4 ): 985 - 992 .
LIU J , QIAN J , MO Q , et al . LncRNA NR2F2-AS1 silencing induces cell cycle arrest in G 0 /G 1 phase via downregulating Cyclin D 1 in colorectal cancer [J]. Cancer Manag Res , 2020 , 12 : 1835 - 1843 .
0
浏览量
19
下载量
4
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621